A Look At Insider Reactions To Biora Therapeutics Inc. (BIOR)

At the last check on Friday, Biora Therapeutics Inc.’s (NASDAQ:BIOR) stock was up $0.04, moving up 4.93 percent to $0.79. The average number of shares traded per day over the past five days has been 989,009 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0922 gain in that time frame. In the last twenty days, the average volume was 1,254,162, while in the previous 50 days, it was 1,638,689.

Since last month, BIOR stock rose 18.88%. Shares of the company fell to $0.6019 on 07/06/22, the lowest level in the past month. A 52-week high of $6.20 was reached on 01/04/22 after having rallying from a 52-week low of $0.56. Since the beginning of this year, BIOR’s stock price has dropped by -64.11% or -$1.2978, and marked a new high 2 times. However, the stock has declined by -87.31% since its 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Biora Therapeutics Inc. (BIOR) last reported insider trading activity 31 days ago on Jul 05. Sarna Surbhi, the Director of the company, disposed of 7,517 shares for $0.61 on Jul 05. It resulted in a $4,585 divestment by the insider.

Financial Health

Based on annual data, BIOR earned $1.25 million in gross profit and brought in $1.25 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -286.50%. Return on equity (ROE) for the past 12 months was 185.10%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BIOR’s revenue fell -22200.0% to -$23.92 million during the quarter, while net income inched up to $0.11 million. While analysts expected Biora Therapeutics Inc. to report -$0.12 quarterly earnings, the actual figure was -$0.08 per share, beating the consensus estimate by 33.30%. During the quarter, the company generated -$19.24 million in EBITDA. The liabilities of Biora Therapeutics Inc. were 179.92 million at the end of its most recent quarter ended March 30, and its total debt was $129.26 million. The value of shareholders’ equity is $184.2 million.

Technical Picture

This quick technical analysis looks at Biora Therapeutics Inc.’s (BIOR) price momentum. With a historical volatility rate of 57.67%, the RSI 9-day stood at 73.68% on 04 August.

With respect to its five-day moving average, the current Biora Therapeutics Inc. price is up by +13.17% percent or $0.0922. At present, BIOR shares trade +14.81% above its 20-day simple moving average and -28.63% percent below its 100-day simple moving average. However, the stock is currently trading approximately +3.30% above its SMA50 and -73.59% below its SMA200.

Stochastic coefficient K was 80.77% and Stochastic coefficient D was 67.61%, while ATR was 0.0560. Given the Stochastic reading of 95.64% for the 14-day period, the RSI (14) reading has been calculated as 64.49%. As of today, the MACD Oscillator reading stands at 0.0377, while the 14-day reading stands at 0.0391.

Analyst Ratings

Biora Therapeutics Inc. (BIOR) has been rated Buy by analysts. According to 0 brokerage firms, BIOR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Biora Therapeutics Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $5.00, the current consensus forecast for the stock is $4.00 – $6.00. Based on these forecasts, analysts predict Biora Therapeutics Inc. (BIOR) will achieve an average price target of $5.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]